Abstract 37P
Background
Nischarin (NISCH) is a scaffolding protein involved in the control of cytoskeletal dynamics. Its tumor suppressive role has been demonstrated in breast cancer; and high expression in tumor tissue was reported as a positive prognostic marker in breast and ovarian cancers. Of interest, there are several approved nischarin agonists used in treatment of hypertension. We have previously found that NISCH is expressed in both tumor cells and cancer-associated fibroblasts (CAFs) in pancreatic ductal adenocarcinoma (PDAC) and that nischarin agonist rilmenidine can limit cancer cell invasion. As the dense tumor stroma makes up to 80% of the bulk tumor tissue in PDAC, and is one of the causes of current treatment failure, the aim of this study was to examine the effects of nischarin agonists on the phenotype of cancer-associated stroma in PDAC.
Methods
NISCH expression and co-localization with CAF markers were examined by immunohistochemistry in PDAC tissue microarray. CAFs were isolated from fresh tumor tissue by the outgrowth method. MTT test was used to evaluate cytotoxicity of nischarin agonist rilmenidine on patient-derived CAFs. Immunoblotting, immunocytochemistry, ELISA and qRT-PCR were used to examine the effects of rilmenidine treatment on the extracellular matrix deposition and cytokine and growth factor production in CAFs and ex vivo cultures of PDAC tumor tissue.
Results
Nischarin was expressed in both aSMA+ and FAP+ cells in the tumor tissue. Patient-derived CAFs were a heterogeneous population, positive for aSMA+ FAP+, collagen I and fibronectin. Rilmenidine treatment of patient-derived CAFs in vitro was not cytotoxic at concentrations achievable in the human plasma. Nevertheless, rilmenidine treatment decreased fractions of both aSMA+ and FAP+ cells in vitro and decreased the production of pro-inflammatory cytokines IL-6, IL-8 and CCL-2. Treatment of ex vivo PDAC tumor cultures for 72h remodeled the extracellular matrix.
Conclusions
Our results imply that rilmenidine treatment in vitro and ex vivo shows a potential for normalizing PDAC tumor-derived CAFs and may be a good candidate for drug repurposing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
European Research Executive Agency; Science Fund of the Republic of Serbia.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
24P - Single cell transcriptomics of the immune cells during chemotherapy in triple-negative breast cancer patients
Presenter: Anastasia Frolova
Session: Poster session 09
25P - Role of AXL activation on adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer
Presenter: Tadaaki Yamada
Session: Poster session 09
26P - Pre-clinical modelling and treatment of BRAF mutated colorectal cancer
Presenter: Mark White
Session: Poster session 09
27P - Extending a classification system for atypical BRAF mutations to improve targeted therapies in colorectal cancer cells
Presenter: Abhinav Madduri
Session: Poster session 09
28P - Xanthine oxidase as a prognostic factor in colorectal cancer metastatic disease
Presenter: Anton Burlaka
Session: Poster session 09
29P - The effect of cancer associated fibroblast-derived activin A on colorectal cancer progression
Presenter: Simone Stang
Session: Poster session 09
30P - Prostaglandin signaling in tumour stroma interaction in colorectal cancer and its impact on the secretome and functional relevance
Presenter: Mario Macia-Guardado
Session: Poster session 09
31P - Cell-free tumor microRNA as early biomarkers of high-grade cervical intraepithelial neoplasia using liquid biopsy
Presenter: Stéphanie Calfa
Session: Poster session 09
32P - Epigenetic reprogramming induced prostaglandin E2 accumulation via overactivated arachidonic acid metabolism during trastuzumab resistance formation of HER2-positive breast cancer
Presenter: yongmei yin
Session: Poster session 09
33P - Visualizing trastuzumab-deruxtecan action in HER2+ breast cancer cells at nanoscale
Presenter: Katia Cortese
Session: Poster session 09